Research Output per year
Fingerprint Dive into the research topics where Alyson Haslam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 14 Similar Profiles
Mindfulness
Medicine & Life Sciences
Adenoma
Medicine & Life Sciences
Meditation
Medicine & Life Sciences
Valsartan
Medicine & Life Sciences
Hand Strength
Medicine & Life Sciences
Diet
Medicine & Life Sciences
Anemia
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2012 2019
5
Citations
(Scopus)
A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals
Herrera-Perez, D., Haslam, A., Crain, T., Gill, J., Livingston, C., Kaestner, V., Hayes, M., Morgan, D., Cifu, A. S. & Prasad, V., 1 Jun 2019, In : eLife. 8, e45183.Research output: Contribution to journal › Article
Open Access
New England
American Medical Association
Medicine
Cardiovascular Diseases
Randomized Controlled Trials
20
Citations
(Scopus)
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Haslam, A., Hey, S. P., Gill, J. & Prasad, V., 1 Jan 2019, In : European Journal of Cancer. 106, p. 196-211 16 p.Research output: Contribution to journal › Review article
Meta-Analysis
Validation Studies
Biomarkers
Survival
Randomized Controlled Trials
3
Citations
(Scopus)
Confirmatory Trials for Drugs Approved on a Single Trial
Haslam, A. & Prasad, V., 1 Jun 2019, In : Circulation. Cardiovascular quality and outcomes. 12, 6, p. e005494Research output: Contribution to journal › Article
Valsartan
Drug Approval
Fish Oils
Pharmaceutical Preparations
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
de Almeida Carvalho, L. M., de Oliveira Sapori Avelar, S., Haslam, A., Gill, J. & Prasad, V., 1 Nov 2019, In : JAMA network open. 2, 11, p. e1916091Research output: Contribution to journal › Article
Open Access
Off-Label Use
Fibroblast Growth Factor Receptors
Neoplasms
Gene Targeting
Pharmaceutical Preparations
22
Citations
(Scopus)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Haslam, A. & Prasad, V., 3 May 2019, In : JAMA network open. 2, 5, p. e192535Research output: Contribution to journal › Article
Open Access
Immunotherapy
Pharmaceutical Preparations
Neoplasms
United States Food and Drug Administration
Melanoma
Press/Media
Most new cancer treatments haven’t been proven to help patients live longer or feel better
6/12/19
2 items of Media coverage
Press/Media
How one bit of medical jargon fuels public confusion about cancer treatments
22/10/19
1 item of Media coverage
Press/Media
Keytruda for Mesothelioma Flops in Phase III Clinical Trial
8/10/19
1 item of Media coverage
Press/Media
Study Finds Nearly 400 Medical Devices, Procedures And Practices That Are Ineffective
13/06/19 → 4/09/19
3 items of Media coverage
Press/Media
Almost 400 medical practices found ineffective in analysis of 3,000 studies
20/08/19
1 item of Media coverage
Press/Media